Merck (MRK) reported disappointing first quarter results on Thursday with sales of $12.1 billion falling 1%, excluding the impact of currency fluctuations.
Merck & Co. and Hanmi Pharmaceutical on Tuesday entered into an exclusive licensing agreement to develop efinopegdutide (formerly HM12525A), an investigational once-weekly therapy …
AstraZeneca Plc’s (AZN) and Merck Co.’s (MRK) Lynparza drug has received a green light from the European Commission (EC) for the treatment of …
Analyst Alex Arfaei of BMO Capital downgraded his rating on Merck & Co., Inc.
Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck …
